Gain Therapeutics Inc. (GANX) Financial Statements (2024 and earlier)

Company Profile

Business Address 4800 HAMPDEN LANE
BETHESDA, MD 20814
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:16,80020,13936,881
Cash and cash equivalents11,7957,31236,881
Short-term investments5,00012,827 
Other undisclosed cash, cash equivalents, and short-term investments5  
Receivables  8782
Prepaid expense742761646
Other undisclosed current assets237104114
Total current assets:17,77921,09137,722
Noncurrent Assets
Operating lease, right-of-use asset459660901
Property, plant and equipment126144106
Long-term investments and receivables  1,941 
Long-term investments  1,941 
Restricted cash and investments343131
Other undisclosed noncurrent assets211231225
Total noncurrent assets:8303,0081,263
TOTAL ASSETS:18,60924,09938,985
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1,3191,626560
Accounts payable1,3191,626560
Deferred revenue1,12255267
Debt119108104
Other liabilities2,1602,1071,403
Other undisclosed current liabilities230229219
Total current liabilities:4,9504,1252,553
Noncurrent Liabilities
Long-term debt and lease obligation4494951,286
Long-term debt, excluding current maturities449495590
Liabilities, other than long-term debt632599329
Deferred revenue95  
Liability, pension and other postretirement and postemployment benefits307158329
Operating lease, liability230442695
Total noncurrent liabilities:1,0811,0951,615
Total liabilities:6,0315,2204,168
Equity
Equity, attributable to parent, including:12,57818,88034,818
Common stock211
Additional paid in capital73,11357,35955,832
Accumulated other comprehensive income (loss)24736(91)
Accumulated deficit(38,516)(20,925)(7,035)
Other undisclosed equity, attributable to parent(22,268)(17,591)(13,891)
Total equity:12,57818,88034,818
TOTAL LIABILITIES AND EQUITY:18,60924,09938,985

Income Statement (P&L) ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
Revenues 55140165
Sublease income  731
Gross profit: 55140165
Operating expenses(22,308)(17,917)(13,991)
Operating loss:(22,253)(17,777)(13,826)
Nonoperating income (expense)
(loss, Foreign Currency Transaction, before Tax)
(429)(96)(73)
Loss from continuing operations before equity method investments, income taxes:(22,682)(17,873)(13,899)
Other undisclosed income from continuing operations before income taxes49437512
Loss from continuing operations before income taxes:(22,188)(17,498)(13,887)
Income tax expense(79)(93)(4)
Loss from continuing operations:(22,268)(17,591)(13,891)
Loss before gain (loss) on sale of properties:(13,891)
Net loss available to common stockholders, diluted:(22,268)(17,591)(13,891)

Comprehensive Income ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
Net loss:(22,268)(17,591)(13,891)
Comprehensive loss:(22,268)(17,591)(13,891)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent21212662
Comprehensive loss, net of tax, attributable to parent:(22,056)(17,464)(13,829)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: